title: A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
abstract: Helicobacter pylori is the cause of chronic active gastritis and predisposes to peptic ulcer disease (PUD). Furthermore, H. pylori is linked to the pathogenesis of gastric lymphoma and gastric cancer. However, treatment of this infection has proven difficult. In the last decade, many antimicrobial compounds have been studied extensively as monotherapy as well as in combination with bismuth or acid-suppressive drugs. The individual drugs and the most important eradication regimens are discussed with special regard to their risks. In the past, highly complex multidrug regimens, fear of adverse effects and frequent eradication failures have hampered the broad acceptance of H. pylori-eradication therapies. Recently, new 1-week, low-dose combination regimens of 2 antibacterials with a proton pump inhibitor have consistently achieved eradication rates of 90% and more with an acceptably low rate of adverse effects. One week's standard triple therapy [tripotassium dicitrato bismuthate (or bismuth salicylate plus metronidazole plus tetracycline or amoxicillin) has been shown to be highly effective and tolerated better in combination with a proton pump inhibitor. This regimen is, however, more complex and has more adverse effects. Therefore, it is not recommended as first-line therapy. Equipped with these therapies physicians can now be strongly encouraged to use H. pylori eradication as the therapy of choice for patients with PUD and even extend this treatment to other H. pylori-associated disease conditions.
authors.affiliation: Department of Gastroenterology, Otto-von-Guericke University, Magdeburg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Hackelsberger
authors.forename: P
authors.initials: P
authors.lastname: Malfertheiner
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D009593:Nitroimidazoles / Q000627:therapeutic use; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000382:microbiology; D054328:Proton Pump Inhibitors; D018570:Risk Assessment; D013754:Tetracyclines / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D006635:Histamine H2 Antagonists; D009593:Nitroimidazoles; D010406:Penicillins; D054328:Proton Pump Inhibitors; D013754:Tetracyclines; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole; D001729:Bismuth